- Home
- ESNT vs MIST Comparison
ESNT vs MIST Comparison
Compare ESNT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESNT | MIST |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 176.3M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ESNT | MIST |
|---|---|---|
| Price | $65.65 | $1.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $68.00 | $8.50 |
| AVG Volume (30 Days) | 662.1K | ★ 10.0M |
| Earning Date | 02-13-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.87 | N/A |
| Revenue | ★ $1,263,558,000.00 | N/A |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $9.57 | ★ N/A |
| Revenue Growth | ★ 2.04 | N/A |
| 52 Week Low | $51.61 | $0.63 |
| 52 Week High | $67.09 | $3.06 |
Technical Indicators
Market Signals| Indicator | ESNT | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 39.74 |
| Support Level | $65.41 | $1.90 |
| Resistance Level | $66.11 | $2.14 |
| Average True Range (ATR) | 0.99 | 0.31 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 73.21 | 27.24 |
Price Performance
Historical ComparisonAbout ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).